ADT and cardiac risks (and how I sold my company for $1.4bn)

Written By Declan Murphy

Professor Neil Fleshner (University of Toronto) drops into the GU Cast studio in Melbourne for an intriguing discussion! First we cover off the underrated topic of cardiac risks in patients starting androgen deprivation therapy and how we can reduce these for the benefit of our patients. Then we talk to Neil about entrepreneurship and his journey into very successful business ventures in recent years. He has some inspiring stories and some great advice for frustrated clinicians out there!

This episode is a Themed Podcast supported by our Bronze Partners, Cipla Australia.

 

Also available as an audio podcast in all the usual places

Declan Murphy
Previous

Proton therapy no better than standard prostate radiotherapy
Next

Happy days for metastatic bladder cancer | Enrique Grande and Andrew Weickhardt